Co-infection with Pansensitive and Multidrug-Resistant Strains of *Mycobacterium tuberculosis*

Michael P. Mendez, Mary E. Landon, Mary K. McCloud, Peter Davidson, and Paul J. Christensen

We report a case of a 23-year-old HIV-negative man with multidrug-resistant *Mycobacterium tuberculosis* that became evident while he was being treated for *M. tuberculosis* that was sensitive to all first-line drugs. This case should alert clinicians to consider co-infection as a possible cause of recrudescent disease.

A 23-year-old HIV-negative man from Somalia immigrated to the United States 1.5 years before seeking treatment for his symptoms. The patient had a 3-week history of dry cough, dyspnea with exertion, pleuritic chest pain, fatigue, weight loss, and night sweats. A chest radiograph showed extensive left hemithorax opacification, a left apical cavitary lesion, and right apical nodular lesions (Figure, panel A). Acid-fast bacillus (AFB) smears and culture were positive for *Mycobacterium tuberculosis*. Drug-susceptibility testing demonstrated sensitivity to all first-line drugs. He received directly observed therapy (DOT), which consisted of isoniazid (300 mg/d), pyrazinamide (1,000 mg/d), rifampin (600 mg/d), and ethambutol (1,200 mg/d).

One month after starting treatment, he had persistent fatigue and shortness of breath and had gained no weight; follow-up chest radiograph showed no change. As a result, he received a prednisone dosage of 40 mg/d with a tapered dose to no prednisone over 2 months (1,2). Thereafter, he improved rapidly both symptomatically and radiographically. His cough abated, and he was unable to produce sputum.

After 5 months of DOT, he again lost weight and felt fatigued. A repeat chest radiograph showed a new small cavitary lesion in the middle lobe of the right lung (Figure, panel B). At that time, repeat sputum sample was smear negative, but culture was positive for multidrug-resistant tuberculosis (MDR TB). Molecular characterization by spoligotyping and mycobacterial interspersed repeat units showed that the isolate from episode 1 differed genetically from that of episode 2 (Table) (3,4). Review of laboratory...
The patient received amikacin 15 mg/kg/d intravenously, moxifloxacin 400 mg/d, cycloserine 750 mg/d, and aminosalicylic acid 8 gm/d in accordance with drug-susceptibility testing. Because of the extent of previous disease, surgical removal of the diseased lung was not performed. He was kept in isolation until 3 sputum smears were AFB negative. He gained weight, his energy increased, and radiographic appearance of his lungs improved. At the time of his discharge, dosage of amikacin was decreased to 300 mg/wk, and cycloserine was decreased to 250 mg/d based on the serum levels of each drug. The patient was instructed to receive treatment for a minimum of 24 months after the first negative sputum culture.

Molecular characterization showed that the 2 strains of *M. tuberculosis* were not related (3,4). Thus, the cause of treatment failure most likely was not due to development of resistance by the infecting strain. Among the >35,000 *M. tuberculosis* isolates characterized by the Centers for Disease Control and Prevention’s National Tuberculosis Genotyping Service (5), no exact genotype matches were found for the isolate from the first episode and 3 exact genotype matches were found for the isolate from the second episode (P. Moonan, pers. comm.). All 3 matched genotypes came from persons originating from the same African region (Somalia and Ethiopia), which suggests a phylogeographic lineage adapted to a particular human population (3,4). As has been previously hypothesized, we conclude that this patient originally harbored both strains (12). The effect of disease at the patient’s initial presentation appears to have been predominantly due to the drug-sensitive strain, as evidenced by his initial clinical and radiographic improvement and sputum conversion. The successful treatment of the drug-susceptible strain and the inherent resistance of the second strain to the first-line medications enabled disease from the MDR TB strain to become apparent.

The initial therapy in this case was complicated by delayed clinical response. The use of corticosteroids as an adjuvant to antituberculosis medications in selected patients with severe disease has been documented to hasten resolution of symptoms and radiographic recovery without delaying clearance of organisms (1,2). Although the role of prednisone treatment in the emergence of the second strain is not clear, we believe the most important factor was the inherent antimicrobial resistance pattern of the second strain.

We report an immunocompetent person with 2 strains of *M. tuberculosis*, one sensitive to all first-line antituberculous drugs and one multidrug resistant. This case demonstrates the ability of genotyping information to identify simultaneous infection with multiple strains of *M. tuberculosis* in a patient in whom treatment failure is suspected. In addition, this case exemplifies the critical importance of clinical monitoring during DOT in the prompt recognition and treatment of patients who have unsuspected simultaneous infections with multiple strains of *M. tuberculosis*.

In patients who are not receiving DOT, a likely cause of treatment failure is nonadherence to the drug regimen (7). In patients who are receiving reliable DOT, deterioration may be explained by cryptic nonadherence, malabsorption, or laboratory error (7). In addition, exogenous reinfection should be considered as a possible reason for treatment failure or disease relapse (8–11). However, an unrecognized cause of treatment failure is mixed infection with >2 strains of *M. tuberculosis* (12–15). As reported previously (12), simultaneous infection with 2 competing strains should be considered when other common reasons are ruled out and a high index of suspicion is present. In the current case, the patient was receiving DOT and demonstrated clinical improvement while receiving an appropriate regimen based on drug-susceptibility testing. When his condition deteriorated clinically and sputum samples were culture positive, several possible causes of treatment failure were quickly discarded, including malabsorption, cryptic nonadherence, and laboratory error/contamination.

As has been previously hypothesized, we conclude that this patient originally harbored both strains (12). The effect of disease at the patient’s initial presentation appears to have been predominantly due to the drug-sensitive strain, as evidenced by his initial clinical and radiographic improvement and sputum conversion. The successful treatment of the drug-susceptible strain and the inherent resistance of the second strain to the first-line medications enabled disease from the MDR TB strain to become apparent.

The initial therapy in this case was complicated by delayed clinical response. The use of corticosteroids as an adjuvant to antituberculosis medications in selected patients with severe disease has been documented to hasten resolution of symptoms and radiographic recovery without delaying clearance of organisms (1,2). Although the role of prednisone treatment in the emergence of the second strain is not clear, we believe the most important factor was the inherent antimicrobial resistance pattern of the second strain.

This case demonstrates the utility of DOT in assisting with prompt recognition of a new infecting strain and
highlights the use of genotyping in the assessment of possible treatment failure. Heightened awareness of possible infection with multiple strains, either from reinfection or co-infection, is critical when monitoring patients who are not improving or who recrudesce despite therapy guided by drug-resistance testing. The use of genotyping is a necessary tool in the evaluation of these patients. In particular, as in this case, a high index of suspicion for co-infection should be applied to persons originating from areas in which *M. tuberculosis* is hyperendemic.

**Acknowledgments**

We thank Patrick Moonan for providing specific genotyping data at the state and national levels and the Colorado Department of Public Health and Environment Tuberculosis Program and Frank Romano for providing epidemiologic information regarding genotype matches.

Genotyping was performed at the Michigan Department of Community Health and the California Department of Health Services under support of a contract from the Centers for Disease Control and Prevention. This work was supported by grants from the Department of Veterans Affairs (Career Development Award to M.P.M., and the Research Enhancement Award Program) and the National Heart, Lung, Blood Institute (HL083844-01 to P.J.C.).

Dr Mendez is an assistant professor in the Division of Pulmonary Critical Care Medicine, Department of Medicine, at the University of Michigan. His interests focus on pulmonary host defense.

**References**

1. Bilaceroglu S, Perim K, Buyuksirin M, Celikten E. Prednisolone: a beneficial and safe adjunct to antituberculosis treatment? A randomized controlled trial. Int J Tuberc Lung Dis. 1999;3:47–54.
2. Smego RA, Ahmed N. A systematic review of the adjunctive use of systemic corticosteroids for pulmonary tuberculosis. Int J Tuberc Lung Dis. 2003;7:208–13.
3. Mathema B, Kurepina NE, Bifani PJ, Kreiswirth BN. Molecular epidemiology of tuberculosis: current insights. Clin Microbiol Rev. 2006;19:658–85. DOI: 10.1128/CMR.00061-05
4. Barnes PF, Cave MD. Molecular epidemiology of tuberculosis. N Engl J Med. 2003;349:1149–56. DOI: 10.1056/NEJMra021964
5. Centers for Disease Control and Prevention. National Genotyping Service Division of Tuberculosis Elimination [cited 2009 Feb 18]. Available from http://www.cdc.gov/tb/pubs/tbfactsheets/genotyping.htm
6. Gagneux S, DeRiemer K, Van T, Kato-Maeda M, de Jong BC, Narayanan S, et al. Variable host-pathogen compatibility in *Mycobacterium tuberculosis*. Proc Natl Acad Sci U S A. 2006;103:2869–73. DOI: 10.1073/pnas.051240103
7. Centers for Disease Control and Prevention. Treatment of tuberculosis. MMWR Recomm Rep. 2005;52(RR-11):1–77.
8. van Rie A, Warren R, Richardson M, Victor TC, Gie RP, Enasar DA, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med. 1999;341:1174–9. DOI: 10.1056/NEJM199910143411602
9. Kriiüner A, Pehme L, Ghebremichael S, Koivula T, Hoffner SE, Mikelsaar M. Use of molecular techniques to distinguish between treatment failure and exogenous reinfection with *Mycobacterium tuberculosis*. Clin Infect Dis. 2002;35:146–55. DOI: 10.1086/340980
10. Chaves F, Dronda F, Alonso-Sanz M, Noriega AR. Evidence of exogenous reinfection and mixed infection with more than one strain of *Mycobacterium tuberculosis* among Spanish HIV-infected inmates. AIDS. 1999;13:615–20. DOI: 10.1097/00002030-19990410-00011
11. Caminero JA, Pena MJ, Campos-Herrero MI, Rodriguez JC, Afonso O, Martin C, et al. Exogenous reinfection with tuberculosis on a European island with a moderate incidence of disease. Am J Respir Crit Care Med. 2001;163:717–20.
12. Garcia SN, Pillus L. A unique class of conditional sir2 mutants displays distinct silencing defects in *Saccharomyces cerevisiae*. Genetics. 2002;162:721–36.
13. Horn DL, Hewlett D Jr, Haas WH, Butler WR, Alfalla C, Tan E, et al. Superinfection with rifampin-isoniazid-streptomycin-ethambutol (RISE)–resistant tuberculosis in three patients with AIDS: confirmation by polymerase chain reaction fingerprinting. Ann Intern Med. 1994;121:115–6.
14. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet. 2001;358:1687–93. DOI: 10.1016/S0140-6736(01)06712-5
15. Braden CR, Morlock GP, Woodley CL, Johnson KR, Colombel AC, Cave MD, et al. Simultaneous infection with multiple strains of *Mycobacterium tuberculosis*. Clin Infect Dis. 2001;33:e42–7. DOI: 10.1086/322635

Address for correspondence: Michael P. Mendez, Pulmonary Section (111G), Veterans Affairs Medical Center, 2215 Fuller Rd, Ann Arbor, MI 48105, USA; email: mpmendez@umich.edu